Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.

To evaluate the oncological outcome and to assess prognostic factors of salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.

We reviewed our single institution, prospectively maintained database of 2043 patients who underwent radical prostatectomy between September 1995 and December 2011.

In this cohort, 149 patients who developed biochemical recurrence after radical prostatectomy and received salvage radiotherapy alone after pelvic magnetic resonance imaging were included. Three-dimensional conformal radiotherapy or intensity-modulated radiotherapy was delivered with a median dose of 70. 0 Gy (66. 0-78. 0 Gy) or 67. 2 Gy (64. 8-70. 0 Gy). Kaplan-Meier and Cox regression analyses were carried out.

With a median follow up of 82 months (range 20-153 months), 55 patients (36. 9%) failed salvage radiotherapy. The 5-year salvage radiotherapy failure-free probability was 53. 6%. On multivariate analysis, pre-salvage radiotherapy prostate-specific- antigen ≥1. 0 ng/mL (P = 0. 003, hazard ratio 3. 592, 95% confidence interval 1. 522-8. 579), pathological stage ≥T3a (P = 0. 004, hazard ratio 2. 261, 95% confidence interval 1. 290-3. 833), pathological Gleason score ≥7 (P = 0. 018, hazard ratio 5. 501, 95% confidence interval 1. 577-21. 221), prostate-specific antigen doubling time

Pre-salvage radiotherapy prostate-specific antigen ≥1. 0 ng/mL, pathological stage ≥T3a, pathological Gleason score ≥7, prostate-specific antigen doubling time

International journal of urology : official journal of the Japanese Urological Association. 2015 Oct 26 [Epub ahead of print]

Wan Song, Hwang Gyun Jeon, Hyun Hwan Sung, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe